SCHEMBL4196144

SCHEMBL4196144

C=C(OC(=O)c1ccc(OC)cc1)c1ccc(OC)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.62
CA2 P00918 5/20 0.62
MAPT P10636 3/20 0.56
CES2 O00748 2/20 0.55
CES1 P23141 2/20 0.55
PARP1 P09874 1/20 0.52
PARP10 Q53GL7 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
PARP4 Q9UKK3 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
PLK1 P53350 1/20 0.48
ELANE P08246 1/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GSK3B P49841 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5082856 0.93 CES2 (0.61) CA1CA2MAPTCES2CES1
SCHEMBL5082794 0.89 MAPT (0.60) CA1CA2MAPTCES2CES1
SCHEMBL5079219 0.89 MAPT (0.60) CA1CA2MAPTCES2CES1
SCHEMBL756485 0.86 NR1I2 (0.56) CA1CA2MAPTCES2CES1
SCHEMBL247019 0.86 CA1 (0.75) CA1CA2MAPTCES2CES1
SCHEMBL16220971 0.85 CA1 (0.62) CA1CA2MAPTCES2CES1
SCHEMBL3385266 0.85 MAPT (0.61) CA1CA2MAPTCES2CES1
SCHEMBL28313267 0.84 CA1 (0.72) CA1CA2MAPTCES2CES1
SCHEMBL28146836 0.83 CA1 (0.60) CA1CA2MAPTCES2CES1
SCHEMBL10004421 0.82 CA1 (0.69) CA1CA2MAPTCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026525-A1 HETEROCYCLIC COMPOUNDS AS PHYSIOLOGICAL COOLANTS SYMRISE AG (DE) 2025-02-06 WO claimed
EP-4469439-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-12-04 EP claimed
WO-2023144326-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-08-03 WO claimed
WO-2025026525-A1 HETEROCYCLIC COMPOUNDS AS PHYSIOLOGICAL COOLANTS SYMRISE AG (DE) 2025-02-06 WO disclosed
EP-4469439-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-12-04 EP disclosed
EP-4247791-A2 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2023-09-27 EP disclosed
WO-2023143741-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-08-03 WO disclosed
WO-2023144326-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2023-08-03 WO disclosed
WO-2022106452-A2 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME SYMRISE AG (DE) 2022-05-27 WO disclosed
EP-3356356-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2018-08-08 EP disclosed
US-20090312384-A1 Benzimidazole As Cooling Compounds GIVAUDAN SA (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312384-A1 Benzimidazole As Cooling Compounds TAS2R41, TAS2R4, TAS2R43 CA1 1033/4885CA2 181/4885MAPT 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.